A Phase 2 Evaluation of the Monoclonal Antibody RAV12, in Combination with Standard Gemcitabine in the Treatment of Patients with Metastatic Pancreatic Cancer
|Effective start/end date||9/3/07 → 10/15/08|
- TGEN DRUG DEV SVC (TD2)
- RAVEN BIOTECHNOLOGIES INC
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.